CJJD:NSC-China Jo-Jo Drugstores Inc. (USD)

EQUITY | Pharmaceutical Retailers | NASDAQ Capital Market

Last Closing

USD 2.9299

Change

-0.07 (-2.33)%

Market Cap

USD 0.03B

Volume

3.02K

Analyst Target

USD 7.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

China Jo-Jo Drugstores Inc is a retail and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. Its segments include retail drugstores, online pharmacy, drug wholesale and herb farming.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc

N/A

USD 14.83B
HITI High Tide Inc

N/A

USD 0.18B
PETS PetMed Express Inc

N/A

USD 0.10B
BIMI Bimi International Medical Inc

N/A

USD 0.01B
MEDS Trxade Group Inc

N/A

USD 8.10M
LFLY Leafly Holdings Inc

N/A

USD 4.37M
LFLYW Leafly Holdings Inc

N/A

N/A
MDVLQ MedAvail Holdings Inc

N/A

N/A

ETFs Containing CJJD

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.41% 50% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.41% 50% F 16% F
Trailing 12 Months  
Capital Gain -82.13% 13% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.13% 13% F 7% C-
Trailing 5 Years  
Capital Gain -99.15% 50% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.15% 50% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -44.72% 22% F 4% F
Dividend Return -44.72% 22% F 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.05% 56% F 34% F
Risk Adjusted Return -91.19% 33% F 9% A-
Market Capitalization 0.03B 38% F 7% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Pharmaceutical Retailers) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.70 40% 15%
Price/Book Ratio 0.30 88% 95%
Price / Cash Flow Ratio -1.64 75% 64%
Price/Free Cash Flow Ratio -1.44 38% 64%
Management Effectiveness  
Return on Equity -107.29% 38% 18%
Return on Invested Capital -20.39% 70% 34%
Return on Assets -13.25% 56% 30%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector